Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3550 clinical trials
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will

myeloid neoplasm
FGFR1
lymphoid malignancy
  • 79 views
  • 14 Dec, 2020
  • 35 locations
featured
COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator

. - Arm A: CD24Fc / Best Available Treatment - Arm B: placebo / Best Available Treatment  CD24Fc will be administered as single dose of 480 mg via IV infusion on

  • 3989 views
  • 17 Jun, 2020
  • 4 locations
featured
Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.  

  • 51 views
  • 22 Feb, 2019
  • 1 location
featured
  • 120 views
  • 23 Nov, 2020
  • 1 location
featured
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of atogepant for the prevention of chronic migraines (PROGRESS)

To evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).  

  • 43 views
  • 10 May, 2019
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet

To assess the efficacy and safety of larazotide 0.25 mg or larazotide 0.50 mg TID versus placebo for the relief of persistent symptoms in adult patients with celiac disease on

gluten
larazotide
  • 41 views
  • 23 Nov, 2020
  • 1 location
featured
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) on slowing progression of mild cognitive impairment due to Alzheimer's disease

A study for patients with mild cognitive impairment due to Alzheimer's disease with short memory loss.  

memantine
dementia
mini-mental state examination
cognitive decline
ginkgo biloba
  • 32 views
  • 08 Dec, 2020
  • 1 location
featured
A Phase III Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.

This study will enroll approximately 800 patients with moderate to severe COPD in 2 subsets. The 24-week subset will enroll approximately 400 patients randomized 1:1 ensifentrine (3 mg

  • 156 views
  • 23 Nov, 2020
  • 1 location
featured
Phase 3 Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

This is a 56-week, placebo controlled study to evaluate the efficacy and safety of the SM04690 injectable suspension 0.07 mg dose in the treatment of knee osteoarthritis (OA).  Both patient

  • 112 views
  • 23 Nov, 2020
  • 1 location
featured
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis  

  • 52 views
  • 23 Nov, 2020
  • 1 location